MULTILAYER-CELL-FACTORY

In today's rapidly evolving biopharmaceutical landscape, despite the emergence of new technologies like single-use bioreactors, the multilayer cell factory maintains an irreplaceable position in vaccine production. This is especially true during responses to large-scale pandemics (like COVID-19), thanks to its unique and well-established advantages.

Optimizing HEK293 transfection efficiency requires more than choosing the right reagent — it demands a coordinated, system-level approach spanning cell health, plasmid purity, reagent optimization, and carefully controlled culture conditions.

From antigen screening to stable cell line expansion, HEK293 delivers high efficiency, strong expression capabilities, and process flexibility. Its unique biological characteristics continue to make it one of the most important cell lines in modern therapeutic development and biomanufacturing.

As gene therapy continues to expand from clinical trials to commercial-scale manufacturing, cell factory systems will remain an essential component of efficient, safe, and standardized viral vector production.

For adherent stem cell types, the cell factory, particularly the Multilayer Cell Factory, has become a widely adopted solution for expanding cell numbers while maintaining controlled culture conditions. However, alongside its advantages, the use of multilayer systems also presents specific technical and process-related challenges that must be carefully addressed.

In modern biopharmaceutical production, the cell factory has become the core system for large-scale cell culture. Whether for vaccine production, monoclonal antibody manufacturing, or viral vector preparation in cell and gene therapy, stable and reproducible cell growth is the foundation of success. The design and implementation of cell factory systems are what make this stability possible.